ScholarIQanswers from OpenAlex

The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas

PaperCitations, authors & open-access status

The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas is a paper indexed in ScholarIQ from OpenAlex.

How many citations does The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas have?

ScholarIQcitation count

The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas has 379 citations in the OpenAlex counts ScholarIQ stores.

When was The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas published?

ScholarIQyear

The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas has 2004 year in the ScholarIQ index.

What is the open-access status of The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas?

ScholarIQoa status

The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas has closed oa status in the ScholarIQ index.

What is the DOI of The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas?

ScholarIQdoi

The DOI for The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas is on the source record.

What is the PMID of The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas?

ScholarIQpmid

The PMID for The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas is on the source record.

What is the OpenAlex record for The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas?

ScholarIQopenalex

The OpenAlex for The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial